Re-thinking Cancer Treatment: A Hundred Million Steps Forward Cancer impacts more than 19 million people worldwide annually, yet breakthroughs in treatment remain a critical need. Umoja Biopharma, a six year old Seattle-based biotech startup that’s tackling this challenge head-on with a game-changing approach. Umoja just raised $100 million in Series C funding to advance their in vivo CAR T-cell therapy, an innovative treatment designed to train the patient’s own body to generate cancer-fighting cells. This approach could redefine the oncology landscape, potentially reducing costs, improving accessibility, and saving countless lives. This round of funding was co-led by Double Point Ventures and DCVC Bio, alongside notable contributions from ARK Investment Management LLC, SoftBank, Alexandria Venture Investments , and others signalling a strong vote of confidence in Umoja’s vision. For context, the global CAR T-cell therapy market is expected to grow at a CAGR of 34.5%, reaching $20 billion by 2030. Umoja’s research could play a pivotal role in shaping this future. This isn’t just about investment or venture capital but reshaping the fight against cancer.
Download the medial app to read full posts, comements and news.